Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme names Darren Snellgrove chief financial officer, effective June 8, 2026

Neutral Impact 4 of 5 leadership Written later

Halozyme appointed Darren Snellgrove, currently Vice President, Investor Relations at Johnson & Johnson, as Chief Financial Officer effective June 8, 2026. Interim CFO David Ramsay will move to an advisory role during a brief transition period. The filing discloses a $670,000 base salary, a bonus target of 50% of salary, and new-hire equity awards with a total grant date value of $7.2 million.

Key points

  • Start date is June 8, 2026; he will report to President and CEO Helen Torley.
  • Base salary of $670,000 and a bonus target of 50% of base salary, prorated in 2026.
  • New-hire equity totals $7.2 million: $3.2 million in RSUs and $4.0 million in stock options, plus a $350,000 sign-on cash bonus.
  • Previously CFO of Johnson & Johnson's Pharmaceutical sector from August 2021 to May 2025.

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECApr 30, 2026, 8:12 AM ET
Accession number0001159036-26-000053

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.